Liquiritin apioside

Liquiritin apioside is an orally available inhibitor of TRPV1 receptor. Liquiritin apioside selectively inhibits laryngeal chemoreflex (LCR) and has no significant effect on mechanoreflex (LMR) . Liquiritin apioside inhibits LCR by inhibiting reactive oxygen species (ROS) and NADPH oxidase, weakening the interaction between ROS and TRPV1. Liquiritin apioside can be used in the research of respiratory-related diseases^[1][2]. In Vitro:Superior laryngeal nerve (SLN) related electrophysiological experiments: Liquiritin apioside (0.1 mM; overnight) can significantly change the electrophysiological kinetics of laryngeal C neuron currents induced by 1.5 μM Capsaicin (HY-10448P)， reducing the current amplitude, increasing the rise time and prolonging the decay time^[1]. In Vivo:Liquiritin apioside (10 μg/μL, intralaryngeal or perineural administration; single dose; 10 min, 20 min) significantly attenuates the apnea, hypertension, and bradycardia responses to the laryngeal chemoreflex (LCR) induced by Capsaicin (HY-10448)， hydrochloric acid (HCl)， and distilled water (DW) in rat pups, but has no significant effect on the laryngeal mechanoreflex (LMR) induced by air pulse (AP) ^[1].
Liquiritin apioside (0.01 g/kg, 0.2 g/kg; po; once daily for 10 days) ameliorates DSS-induced colitis in mice, and modulates the gut microbial diversity and composition^[2].